Table 1.
Univariate sensitivity analysis
| Parameter involved in the sensitivity analysis | Avoided costs | Cost for service | Net cost benefit for the whole population (75 patients) |
|---|---|---|---|
| Prevalence of inappropriate prescriptions (%) | |||
| 28 | 4597€ | 4323€ | −274€ |
| 25 | 3063€ | 4323€ | 461€ |
| Minimal costs for each pathology | 363€ | 4323€ | 3959€ |
| Reduction of the median cost for each pathology (%) | |||
| 20 | 6363€ | 4323€ | −2040€ |
| 30 | 5567€ | 4323€ | −1244€ |
| 40 | 4772€ | 4323€ | −449€ |
| 45 | 4373€ | 4323€ | −50€ |
| 20% increase of the median cost for each pathology | 8440€ | 4323€ | −4117€ |
| Nesbit probability at 0.1 for all patients | 4391€ | 4323€ | −68€ |
| 30% reduction of drug costs (generics cost) | 7954€ | 4070€ | −3884€ |
Cost for service includes pharmacist wages and drug cost. The costs used for the calculation were determined in 2013. The median ADE cost estimates and the appropriateness of the prescriptions were gradually reduced until the cut-off of the net benefit for the clinical pharmacist intervention was reached.
ADE, adverse drug events.